F-18 Fluoromisonidazole for Imaging Tumor Hypoxia: Imaging the Microenvironment for Personalized Cancer Therapy
- 1 March 2015
- journal article
- review article
- Published by Elsevier in Seminars in Nuclear Medicine
- Vol. 45 (2) , 151-162
Abstract
No abstract availableKeywords
This publication has 111 references indexed in Scilit:
- A prospective clinical trial of tumor hypoxia imaging with 18F-fluoromisonidazole positron emission tomography and computed tomography (F-MISO PET/CT) before and during radiation therapyJournal of Radiation Research, 2013
- Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancerRadiotherapy and Oncology, 2012
- The updated biology of hypoxia‐inducible factorThe EMBO Journal, 2012
- Hypoxia imaging with [F-18] FMISO-PET in head and neck cancer: Potential for guiding intensity modulated radiation therapy in overcoming hypoxia-induced treatment resistanceRadiotherapy and Oncology, 2011
- Preclinical evaluation and validation of [ 18 F]HX4, a promising hypoxia marker for PET imagingProceedings of the National Academy of Sciences, 2011
- Molecular Imaging–Based Dose Painting: A Novel Paradigm for Radiation Therapy PrescriptionSeminars in Radiation Oncology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Hypoxia and Hypoxia-Inducible Factors: Master Regulators of MetastasisClinical Cancer Research, 2010
- Comparative pharmacokinetics, biodistribution, metabolism and hypoxia-dependent uptake of [18F]-EF3 and [18F]-MISO in rodent tumor modelsRadiotherapy and Oncology, 2008
- Fluorine-18-Labeled Fluoromisonidazole Positron Emission and Computed Tomography-Guided Intensity-Modulated Radiotherapy for Head and Neck Cancer: A Feasibility StudyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008